Streetbeat News

Stock Prices

EW

Edwards Lifesciences (NYSE:EW) has received mixed analyst ratings in the last quarter, with 4 bullish, 2 somewhat bullish, 5 indifferent, and 1 somewhat bearish. The average price target among these analysts is $78.33, which is higher than the current price of $65.75, suggesting an upside. However, this target is a 12.86% decrease from the previous target of $89.89. Analysts' ratings are based on various data sources, including company calls, financial statements, and insider information.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

ETNB

Over the past 3 months, 5 analysts have provided ratings for 89bio (NASDAQ:ETNB), with 2 being bullish and 3 somewhat bullish. There have been no indifferent, somewhat bearish, or bearish ratings. The average price target is now $29.0, down from the previous $32.33, which is still a significant upside from the current price of $7.922. Analysts typically review stocks quarterly and may adjust their predictions based on various financial metrics and company performance.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

CMND

SPRC

Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have reported positive preclinical trial results for a combination therapy treating obesity and metabolic disorders. The therapy combines Clearmind's psychedelic MEAI and SciSparc's anti-inflammatory PEA. The trial found optimal dosages that increased metabolic processes and fat burn while reducing appetite and meal sizes without affecting animal viability. Clearmind also announced a 1-for-30 reverse share split effective today.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 1:00 pm

NNDM

Nano Dimension (NASDAQ:NNDM) reported Q3 EPS of $(0.26), which is unchanged from the same period last year. However, sales increased by 21.62% to $12.16M from $10.00M in the same quarter the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:57 pm

LQR

LQR House Inc. (NASDAQ:LQR) announced a 1-for-60 reverse stock split effective November 30, 2023, to comply with Nasdaq's minimum bid price requirement. The company's Board of Directors and majority shareholders unanimously approved the measure after a non-compliance notification from Nasdaq. The reverse stock split is intended to increase the per-share price to meet the $1.00 minimum bid price rule. CEO Sean Dollinger emphasized efforts in transparency and growth through partnerships and acquisitions. The split will adjust outstanding convertible securities and no fractional shares will be issued, with all fractions rounded up.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:48 pm

BABA

PDD

PDD Holdings Inc (NASDAQ:PDD) reported a significant third-quarter FY23 revenue increase of 94% year-on-year to $9.44 billion, surpassing the consensus estimate of $7.69 billion. Adjusted earnings per ADS were $1.55, beating the $1.23 consensus. The company saw a 39% increase in online marketing services revenue and a 315% jump in transaction services revenue. PDD's adjusted operating profit rose 47% Y/Y to $2.48 billion. The company has $27.8 billion in cash and equivalents and generated $4.46 billion in operating cash flow. PDD shares surged 14.68% to $135.00 in premarket trading. The stock has risen 39.3% YTD.

Portfolio Pulse from Anusuya Lahiri

November 28, 2023 | 12:44 pm

AOS

HIBB

HRB

X

Insiders at H&R Block, United States Steel, Hibbett, and A. O. Smith have recently sold shares of their companies. H&R Block's CFO sold shares worth $2.21 million, United States Steel's SVP sold shares worth $175,000, Hibbett's SVP and CIO sold shares worth $129,470, and A. O. Smith's Director sold shares worth $205,227. These sales occurred after each company reported strong quarterly results. Insider sales can indicate various sentiments and should not be the sole basis for investment decisions.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 12:42 pm

PYXS

Pyxis Oncology announced the appointment of Ken Kobayashi as Chief Medical Officer, effective November 27, 2023. This strategic hire could strengthen the company's leadership as it advances its oncology pipeline.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:34 pm

ALAR

Alarum Technologies (NASDAQ:ALAR) reported Q3 earnings of $0.03 per share, missing the consensus estimate of $0.07 by 57.14%. However, the company saw a 142.86% increase over the previous year's losses of $(0.07) per share. Sales reached $6.75M, surpassing the $6.60M estimate by 2.27% and marking a 40.27% increase from the $4.81M reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:31 pm

CROX

Raymond James analyst Rick Patel upgraded Crocs, Inc. (NASDAQ:CROX) from Outperform to Strong Buy and increased the price target from $98 to $115.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:28 pm